Weight loss to slow atrial fibrillation progression
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at whether losing weight can help reduce the progression of atrial fibrillation (an irregular heartbeat). It might help people who are overweight and have AF symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptoms of atrial fibrillation that come and go or last between 7 days and 6 months.
- You are currently in normal heart rhythm (no AF episode right now).
- Your BMI is 27 or higher (considered overweight).
- You are older than 18 years.
- You have had at least one ECG-documented AF episode in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a program of exercise and healthy eating changes can reduce how often atrial fibrillation (AFib) happens and help you lose weight. It may be a good fit if you are overweight, have AFib, and are ready to make lifestyle changes.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
This trial tests whether a weight-loss medication called tirzepatide (given as a shot) helps prevent atrial fibrillation from coming back after a catheter ablation procedure. It is for people who have both obesity and atrial fibrillation, and it may help improve heart health by reducing weight and inflammation.
This study tests whether special care strategies can help obese patients have better results after a catheter ablation procedure for atrial fibrillation (a heart rhythm problem). Catheter ablation uses heat or cold to fix the irregular heartbeats.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This study tests whether a weekly injection of tirzepatide (a medicine that helps with weight loss and blood sugar) can lower the chance of atrial fibrillation coming back after a heart procedure called catheter ablation. It may help people who are overweight or have obesity and are having this procedure.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.